Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00451646
Recruitment Status : Completed
First Posted : March 23, 2007
Last Update Posted : August 27, 2010
Sponsor:
Information provided by:
Fresenius Kabi

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this study is to evaluate the safety and tolerance of SMOFlipid 20% in comparison to a standard lipid emulsion Intralipid 20% in patients requiring long-term parenteral nutrition. The safety and tolerance will be evaluated by biochemistry, hematology and coagulation variables, vital signs and adverse events. Further objectives to evaluate are the influence of SMOFlipid 20% on inflammation processes, the efficacy of anti-oxidative properties of vitamin E supplemented to SMOFlipid 20%, and the fatty acid pattern in red blood cells and serum.

Condition or disease Intervention/treatment Phase
Parenteral Nutrition Drug: SMOF lipid and Intralipid Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomised Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition
Study Start Date : October 2007
Actual Primary Completion Date : October 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

Drug Information available for: SMOFlipid

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 1
SMOFlipid
 Drug: SMOF lipid and Intralipid
1-2 g, 5-7 days, 28 days
Active Comparator: 2
Intralipid
 Drug: SMOF lipid and Intralipid
1-2 g, 5-7 days, 28 days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety and tolerability of SMOFlipid 20% assessed by laboratory and clinical parameters (biochemistry, hematology, coagulation), vital signs, adverse events (AEs) as well as inflammation and lipid peroxidation variables [ Time Frame: day 0, week 2, week 4 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • In- and out-patients in need of parenteral nutrition due to inability to sustain an adequate oral/enteral food intake for at least 4 weeks
  • Written consent from the subject

Exclusion Criteria:

  • Known hypersensitivity to fish-, egg-, soy-, or peanut-protein or to any of the active substances or excipients
  • Known type IV hyperlipidemia, disturbances in lipid metabolism or hypertriglyceridemia
  • Severe liver insufficiency
  • Severe blood coagulation disorders
  • Subjects with chronic stable renal insufficiency defined as S-creatinine value of > 25 mg/l (200 µmol/l) or receiving dialysis/hemofiltration therapy
  • General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration
  • Unstable conditions
  • Unstable angina pectoris
  • Acute shock
  • Chemotherapy within 4 weeks before start of the trial
  • Chemotherapy during the trial
  • Subjects for whom the trial treatment is not appropriate
  • Female patients must be surgically sterile; or postmenopausal for at least two years; or if of childbearing potential must have a negative serum pregnancy test and must agree to maintain adequate birth control practice during the study.
  • Participation in another clinical study with an investigational drug or an investigational medical device within one month prior to start of study or during the study
  • Prior inclusion in the present study
  • Any other feature that in the opinion of the investigator should preclude study participation
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00451646


Locations
Layout table for location information
Australia, New South Wales
North Shore Private Hospital
Saint Leonards, New South Wales, Australia, 2065
Australia, Victoria
Monash Medical Centre
Melbourne, Victoria, Australia, 3168
Denmark
Aalborg University Hospital, Department of Medical Gastroenterology
Aalborg, Denmark, 0 9000
Rigshospitalet, Department of Medical Gastroenterology
Copenhagen, Denmark, 0 2100
France
Hopital Beaujon
Clichy la Garenne, France, 92110
Hopital Edouard Herriot, Unite de Nutrition a Domicile Lyon
Lyon, France, 69437
Israel
Beilinson Medical Center, Department of Surgery "B"
Petah Tiqwa, Israel, 0 45100
Netherlands
University Medical Center
Nijmegen, Netherlands, 6500 HB
Poland
Wydzial Lekarski I Katedra Chirurgii Ogolnej
Krakow, Poland, 31-501
Samodzielny Publiczny Szpital Kliniczny im. Prof. W. Orłowskiego
Warsaw, Poland, 00-416
United Kingdom
Hope Hospital
Manchester, United Kingdom, 0M6 8HD
University Hospital, Queen's Medical Centre
Nottingham, United Kingdom, NG7 2UH
Sponsors and Collaborators
Fresenius Kabi
Investigators
Layout table for investigator information
Principal Investigator: Jon Shaffer, MD Hope Hospital, Manchester, United Kingdom
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for additonal information
Responsible Party: Dr. Ingrid Mueller, Fresenius Kabi Deutschland GmbH
ClinicalTrials.gov Identifier: NCT00451646     History of Changes
Other Study ID Numbers: 05-SMOF-006
First Posted: March 23, 2007    Key Record Dates
Last Update Posted: August 27, 2010
Last Verified: October 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Soybean oil, phospholipid emulsion
Fat Emulsions, Intravenous
Parenteral Nutrition Solutions
Pharmaceutical Solutions